ISA announces successful closing of EUR 26 million funding round

Oegstgeest, 13 July 2021, ISA announces the closing of a EUR 26 million funding round with participation from new investors including Invest-NL and existing investors including Regeneron. The proceeds of this round will be used to advance the lead product ISA101b towards first marketing authorization as well as to broaden the clinical pipeline of immunotherapies based on the Synthetic Long Peptide (SLP®) platform technology.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...